In a research report issued Thursday, Wedbush analyst David Nierengarten maintained an Outperform rating on NPS Pharmaceuticals (NASDAQ:NPSP) with a price target of …
In a research report issued today, Wedbush analyst David Nierengarten reiterated a Neutral rating on Infinity Pharma (NASDAQ:INFI) with a $15 price target, …
In a research report published today, Wedbush analyst David Nierengarten reiterated an Outperfom rating on Medivation (NASDAQ:MDVN) with a $109 price target, ahead of the …
In a research report issued October 6 to investors, Wedbush analyst David Nierengarten reiterated a Neutral rating on Sunesis Pharmaceuticals (NASDAQ:SNSS) and significantly reduced his …
In a research report published today, Wedbush analyst David Nierengarten reiterated an Outperform rating on MacroGenics (NADAQ:MGNX) with a $52 price target, following MGNX’s …
In a research note released today, Wedbush analyst David M. Nierengarten reiterated an Outperform rating on Endocyte (NASDAQ:ECYT) with a $26 price target, …
In a research note published yesterday, Wedbush analyst David Nierengarten reaffirmed an Outperform rating on Anacor Pharmaceuticals (NASDAQ:ANAC) with a $35 price target, …
In a report published yesterday, Wedbush analyst David Nierengarten assigned an Outperform rating on NPS Pharmaceuticals Inc. (NASDAQ:NPSP) ahead of the release of the …
In a research report issued today, Wedbush analyst David Nierengarten reiterated an Outperform rating on Sunesis Pharmaceuticals (SNSS) with a $10 price target, as the company should be unblinding …
In a research report published today, Wedbush analyst David Nierengarten reiterated an Outperform rating on Oncothyreon Inc. (NASDAQ:ONTY) and lowered his price target …
